This redundancy between integrins β1 and β3 could be one of the reasons for the treatment failure of cilengitide in patients with GBM and prompted us to look into FAK as a common downstream target of integrins β1 and β3 (44, 45). This evidence concerns the gene PTK2 and glioblastoma.